EpimAb Biotherapeutics to Present Novel Prodrug T-Cell Engager Platform at AACR

The biotechnology company will showcase its innovative cancer treatment technology at the upcoming cancer research conference.

Apr. 15, 2026 at 1:19am

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the complex internal structure of a cancer cell, conveying the scientific and medical nature of EpimAb's novel therapeutic platform.EpimAb's innovative cancer treatment technology aims to precisely target and eliminate tumor cells while minimizing harm to healthy tissue.San Diego Today

EpimAb Biotherapeutics, a clinical-stage biotechnology company specializing in bispecific antibodies and T-cell engagers, will present its novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. The company's posters will feature details on the ProTCE Platform and its initial preclinical proof-of-concept candidate, EM33.

Why it matters

EpimAb's presentation at AACR validates the global competitiveness and clinical potential of its proprietary biotherapeutic innovations, which aim to address key unmet medical needs and develop safer, more effective cancer treatments for patients worldwide.

The details

EpimAb's posters will highlight the company's novel ProTCE Platform, which leverages prodrug technology to create T-cell engagers with potent and tumor-restricted activity. The presentation will provide details on the platform's capabilities and the initial preclinical data for the EM33 ProTCE candidate.

  • The 2026 AACR Annual Meeting will take place from April 17-22, 2026 in San Diego, California.
  • EpimAb's ProTCE Platform and EM33 poster presentation is scheduled for Monday, April 20, 2026 from 9:00AM - 12:00PM local time.

The players

EpimAb Biotherapeutics

A clinical-stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, utilizing proprietary platforms like FIT-Ig and MAT-Fab.

Dr. Chengbin Wu

The Founder and CEO of EpimAb Biotherapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to present our Prodrug T-cell engager technology platform at AACR annual conference. This achievement validates the global competitiveness and clinical translation potential of our proprietary innovations, marking a key milestone in advancing the company's R&D capabilities.”

— Dr. Chengbin Wu, Founder and CEO, EpimAb Biotherapeutics

What’s next

EpimAb plans to continue advancing its ProTCE Platform and the EM33 candidate through further preclinical development, with the goal of initiating clinical trials in the near future.

The takeaway

EpimAb's presentation at the prestigious AACR conference showcases the company's innovative approach to developing safer and more effective cancer treatments using its proprietary bispecific antibody and T-cell engager technologies. This milestone highlights EpimAb's growing global prominence in the biopharmaceutical industry.